Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spyre Therapeutics (NASDAQ: SYRE) announced that management will participate in three investor conferences in November 2025: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 10:00 am ET, the Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 8:40 am ET, and the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 8:00 am GMT. Live audio webcasts and replays will be available on the company’s investor events website at https://ir.spyre.com/events-and-presentations.
Details
News Market Reaction – SYRE
On Oct 30, the first trading day after this news, SYRE closed 1.80% above the previous close.
Data tracked by StockTitan Argus for the Oct 30 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Guggenheim 2nd Annual Healthcare Innovation Conference - Boston
Date: Monday, November 10, 2025
Fireside Time: 10:00 am ET
Event: Stifel 2025 Healthcare Conference – New York
Date: Tuesday, November 11, 2025
Fireside Time: 8:40 am ET
Event: Jefferies Global Healthcare Conference - London
Date: Wednesday, November 19, 2025
Fireside Time: 8:00 am GMT
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
For Investors:
Eric McIntyre, Spyre Therapeutics
VP of Finance and Investor Relations
Eric.mcintyre@spyre.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.